Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

The 2022 Tandem Meetings | Advances in tools for genetic engineering of HSCs

Luigi Naldini • 7 Apr 2022
The 2022 Tandem Meetings
General

Luigi Naldini, MD, PhD, San Raffaele Telethon Institute for Gene Therapy, Milano, Italy, gives an overview of current and emerging genetic engineering platforms for hematopoietic stem cells (HSCs). Lentiviral vector-mediated gene transfer is currently the most advanced platform for HSC gene therapy. Other promising tools including CRISPR-Cas9 gene editing have entered early clinical testing. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

More from Luigi Naldini

1:32
Lentiviral vectors for HSC gene therapy
Luigi Naldini • 7 Apr 2022
1:09
Reducing the toxicity of conditioning in HSC gene therapy
Luigi Naldini • 7 Apr 2022

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals